Filter the latest scan's published facts — sector, size, yield, valuation — or rank them with a preset: cheapest, fastest growing, most profitable. Every view shows what is in the filings and prices; none ranks opportunity. The model behind the statuses showed no predictive power, and nothing here is a recommendation.
Scan of 2026-08-31 · 2,409 names scored · prices as of that date
Lowest valid-in-sector trailing valuation multiples today, latest scan: each name's sector percentiles on earnings yield, FCF yield, P/S, P/B, P/TBV and P/CFO, averaged (only the metrics valid in its sector — a REIT is never ranked by GAAP P/E here). “Cheapest” is a fact about trailing multiples versus sector peers, not a forecast that they re-rate.
Tested the unforgiving way: a composite ranking built from these same point-in-time filings (2017-01-31 to 2026-05-29) showed no measurable predictive power (mean IC 0.0168, t = 1.21), and its top quintile did not beat holding everything even before costs. Ranks like these describe today's record; they do not predict tomorrow's return.
284 names — page 3 of 6 · sector: Pharma & chemicals · Export CSV
| # | Ticker | Company | Sector | Cheap composite | P/E (trailing) | P/S (trailing) | FCF yield | Own 5y |
|---|---|---|---|---|---|---|---|---|
| 101 | SION | Sionna Therapeutics, Inc. Common Stock | Pharma & chemicals | 52.0 | — | — | -26.5% | — |
Never the absolute multiple alone. A P/E of 9 is a fact; whether it is low depends on what you hold it against.
The five-year window is the empirically privileged one. Cheap against its sector and cheap against its own history are different claims, and a stock can be one without being the other — which is the whole reason both columns are shown rather than blended into a single score.
| 102 | CTNM | Contineum Therapeutics, Inc. Class A Common Stock | Pharma & chemicals | 51.8 | — | — | -9.5% | — |
| 103 | SLDB | Solid Biosciences Inc. Common Stock | Pharma & chemicals | 51.7 | — | — | -18.3% | +0.9σ |
| 104 | HXL | Hexcel Corporation | Pharma & chemicals | 51.6 | 62.6× | 3.8× | 2.8% | +0.0σ |
| 105 | KROS | Keros Therapeutics, Inc. Common Stock | Pharma & chemicals | 51.1 | — | 6.6× | -26.6% | −1.4σ |
| 106 | BCPC | Balchem Corporation | Pharma & chemicals | 51.1 | 35.7× | 5.3× | 3.9% | +0.9σ |
| 107 | JANX | Janux Therapeutics, Inc. Common Stock | Pharma & chemicals | 51.0 | — | 80.8× | -7.1% | −0.3σ |
| 108 | MLYS | Mineralys Therapeutics, Inc. Common Stock | Pharma & chemicals | 51.0 | — | — | -6.4% | — |
| 109 | ARVN | Arvinas, Inc | Pharma & chemicals | 50.9 | — | 2.3×FY | -43.3% | −1.1σ |
| 110 | ECL | Ecolab, Inc. | Pharma & chemicals | 50.6 | 37.8× | 4.8× | 2.3% | −0.3σ |
| 111 | NGVT | Ingevity Corporation | Pharma & chemicals | 50.5 | — | 2.1× | 10.2% | +1.5σ |
| 112 | GLUE | Monte Rosa Therapeutics, Inc. Common Stock | Pharma & chemicals | 50.2 | — | 27.4× | -1.7% | +0.8σ |
| 113 | JNJ | Johnson & Johnson | Pharma & chemicals | 50.1 | 30.4× | 6.6× | 2.8% | −2.5σ |
| 114 | AMGN | Amgen Inc | Pharma & chemicals | 50.0 | 29.7× | 6.2× | 3.7% | −1.7σ |
| 115 | DNTH | Dianthus Therapeutics, Inc. Common Stock | Pharma & chemicals | 49.8 | — | — | -2.3% | +0.7σ |
| 116 | AXSM | Axsome Therapeutics, Inc | Pharma & chemicals | 49.6 | — | 14.4× | -0.7% | +1.3σ |
| 117 | BCAX | Bicara Therapeutics Inc. Common Stock | Pharma & chemicals | 49.0 | — | — | -7.7% | — |
| 118 | MNPR | Monopar Therapeutics Inc. Common Stock | Pharma & chemicals | 49.0 | — | — | -1.3% | +0.5σ |
| 119 | CRSP | CRISPR Therapeutics AG | Pharma & chemicals | 48.8 | — | — | -7.3% | −0.5σ |
| 120 | IDYA | IDEAYA Biosciences, Inc. Common Stock | Pharma & chemicals | 48.8 | — | 16.1×FY* | -2.5% | +0.6σ |
| 121 | BEAM | Beam Therapeutics Inc. Common Stock | Pharma & chemicals | 48.7 | — | 18.4× | -12.7% | −0.5σ |
| 122 | NRC | NRC Health Common Stock | Pharma & chemicals | 48.5 | — | 3.4× | 3.7% | −0.2σ |
| 123 | NXTC | NextCure, Inc. Common Stock | Pharma & chemicals | 48.3 | — | — | -218.9% | −0.5σ |
| 124 | MEDP | Medpace Holdings, Inc. Common Stock | Pharma & chemicals | 48.3 | 36.8× | 6.3× | 4.2% | −0.3σ |
| 125 | PCVX | Vaxcyte, Inc. Common Stock | Pharma & chemicals | 48.3 | — | — | -8.9% | −0.7σ |
| 126 | HALO | Halozyme Therapeutics, Inc. | Pharma & chemicals | 48.2 | 36.2× | 8.4× | 5.3% | −0.2σ |
| 127 | ROIV | Roivant Sciences Ltd. Common Shares | Pharma & chemicals | 48.1 | — | — | -3.0%FY | +1.2σ |
| 128 | SXT | Sensient Technology Corporation | Pharma & chemicals | 48.1 | 39.5× | 3.4× | 0.4% | −0.4σ |
| 129 | ENTA | Enanta Pharmaceuticals, Inc | Pharma & chemicals | 47.9 | — | 5.6× | -4.8% | +0.9σ |
| 130 | ORIC | Oric Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 47.8 | — | — | -8.3% | +0.9σ |
| 131 | OLMA | Olema Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 47.8 | — | — | -16.3% | +0.6σ |
| 132 | LENZ | LENZ Therapeutics, Inc. Common Stock | Pharma & chemicals | 47.8 | — | 7.8× | -53.5% | −1.0σ |
| 133 | TECX | Tectonic Therapeutic, Inc. Common Stock | Pharma & chemicals | 47.4 | — | — | -11.6% | +0.9σ |
| 134 | CAPR | Capricor Therapeutics Inc | Pharma & chemicals | 47.2 | — | — | -17.5% | −0.7σ |
| 135 | BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | Pharma & chemicals | 47.1 | — | — | -18.5% | — |
| 136 | CRVS | Corvus Pharmaceuticals, Inc. | Pharma & chemicals | 47.0 | — | — | -3.0% | +1.0σ |
| 137 | VCEL | Vericel Corporation | Pharma & chemicals | 46.7 | 94.8× | 7.0× | 2.3% | +2.2σ |
| 138 | FDMT | 4D Molecular Therapeutics, Inc. Common Stock | Pharma & chemicals | 46.3 | — | 8.4× | -17.6% | +0.4σ |
| 139 | NGNE | Neurogene, Inc. Common Stock | Pharma & chemicals | 46.2 | — | — | -14.7% | +0.7σ |
| 140 | ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | Pharma & chemicals | 46.1 | — | 7.7× | -14.0% | +0.0σ |
| 141 | LYEL | Lyell Immunopharma, Inc. Common Stock | Pharma & chemicals | 46.0 | — | — | -40.2% | +0.1σ |
| 142 | TYRA | Tyra Biosciences, Inc. Common Stock | Pharma & chemicals | 45.8 | — | — | -6.9% | +0.5σ |
| 143 | IMUX | Immunic, Inc. Common Stock | Pharma & chemicals | 45.8 | — | — | -37.8% | +1.0σ |
| 144 | PRM | Perimeter Solutions, Inc. | Pharma & chemicals | 45.6 | — | 7.0× | 1.9% | −0.3σ |
| 145 | XENE | Xenon Pharmaceuticals Inc | Pharma & chemicals | 45.5 | — | — | -5.3% | +0.0σ |
| 146 | ANTX | AN2 Therapeutics, Inc. Common Stock | Pharma & chemicals | 45.5 | — | — | -15.7% | +1.1σ |
| 147 | PRTA | Prothena Corporation plc Ordinary Shares | Pharma & chemicals | 45.3 | — | 8.6× | -16.4% | −0.4σ |
| 148 | BIOA | BioAge Labs, Inc. Common Stock | Pharma & chemicals | 45.2 | — | 40.9× | -21.0% | — |
| 149 | RAPP | Rapport Therapeutics, Inc. Common Stock | Pharma & chemicals | 45.2 | — | — | -3.5% | — |
| 150 | TNXP | Tonix Pharmaceuticals Holding Corp. | Pharma & chemicals | 45.1 | — | 11.4× | -65.2% | +0.5σ |
"Cheap composite" is a 0–100 position among valid sector peers — the mean of the component metrics' sector percentiles. "—" means the scan published no figure, deliberately. "n/a — masked" means the metric is misleading in that name's sector (a REIT's GAAP P/E, a bank's FCF yield) — hover for the reason, which comes from the same sector-validity rules the composite itself respects. An FY tag marks a trailing-year figure built from an annual filing; hover for what that means.